What is Travere Therapeutics, Inc.'s total revenue?

Travere Therapeutics, Inc. (TVTX) reported total revenue of $127.2M in Q1 2026.

How has Travere Therapeutics, Inc.'s total revenue changed year-over-year?

Travere Therapeutics, Inc.'s total revenue increased by 55.6% year-over-year, from $81.73M to $127.2M.

What is the long-term trend for Travere Therapeutics, Inc.'s total revenue?

Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s total revenue has grown at a 64.9% compound annual growth rate (CAGR), from $109.46M to $490.73M.

What does total revenue mean?

The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Travere Therapeutics, Inc. TVTX Total Revenue

Total Revenue at other companies

Vertex PharmaceuticalsVRTX

$2.99B+7.8%

BridgeBio PharmaBBIO

$194.52M+66.8%

Arrowhead ResearchARWR

$73.74M-86.4%

LQD

Liquidia CorporationLQDA

——

PTC TherapeuticsPTCT

——

Scholar RockSRRK

——

Segments

By segment

See full

Reportable Segment$127.2M+55.6%

By product

See full

License and collaboration revenue$2.71M-54.1%

Other financials

Income statement

See full

Gross profit$125.2M+62.5%

Operating income-$36.9M+13.5%

Net income-$37.1M+10.0%

EPS (diluted)-$0.40+14.9%

Balance sheet

See full

Cash & equivalents$78.4M+26.6%

Total debt$15.6M-82.6%

Total equity$98.7M+201%

Total assets$555.2M+1.2%

Cash flow

See full

Operating cash flow-$40.4M+4.3%

CapEx$140.0K—

Free cash flow-$42.5M+28.1%

Valuation

See full

Market cap$5.13B+72.3%

Enterprise value$5.07B+65.5%

P/S9.6×-1.3×

Profitability

See full

Gross margin98.6%+2.6pp

Operating margin-10.6%-5.0pp

Net margin-20.3%-9.5pp

FCF margin-133.9%-34.4pp

Returns & leverage

See full

Return on equity-706%-1,302pp

Debt / equity0.2×-2.6×

Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s total revenue?: Travere Therapeutics, Inc. (TVTX) reported total revenue of $127.2M in Q1 2026.
How has Travere Therapeutics, Inc.'s total revenue changed year-over-year?: Travere Therapeutics, Inc.'s total revenue increased by 55.6% year-over-year, from $81.73M to $127.2M.
What is the long-term trend for Travere Therapeutics, Inc.'s total revenue?: Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s total revenue has grown at a 64.9% compound annual growth rate (CAGR), from $109.46M to $490.73M.
What does total revenue mean?: The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.